A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study-Reference-Cited by-同舟云学术

A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

Published:2014-02-24 Issue:10 Volume:55 Page:2301-2304
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kirschbaum Mark H.,Foon Kenneth A.,Frankel Paul,Ruel Christopher,Pulone Bernadette,Tuscano Joseph M.,Newman Edward M.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2013.877134

Reference17 articles.

1. Evaluation of prognostic factors in AML

2. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

3. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

4. Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

5. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Histone Deacetylase Inhibitor in Acute Myeloid Leukemia;PROG BIOCHEM BIOPHYS;2024

2. Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review;Frontiers in Oncology;2024-02-21

3. Differentiating Acute Myeloid Leukemia Stem Cells/Blasts;Reference Module in Biomedical Sciences;2024

4. Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy;Frontiers in Immunology;2023-09-22

5. New Approaches to Targeting Epigenetic Regulation in Bladder Cancer;Cancers;2023-03-20